How do you approach aspirin chemoprevention when bleeding risk is borderline in a patient with Lynch syndrome?

How do the results of the CaPP3 trial inform your approach? PMID 42425127

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

Do you always send SDHB by IHC for workup of GIST or is NGS that includes SDHB sufficient?

Are you using tarlatamab for neuroendocrine carcinomas (NECs) and poorly differentiated neuroendocrine tumors of GI (non-lung) origins?

Which patients, if any, do you revert back to ultrasound screening for HCC after prior diagnosis/definitive treatment of HCC?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.